These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 20022651

  • 21. Period prevalence of abnormal glucose tolerance and cardiovascular risk factors among obese children attending an obesity centre in Italy.
    Invitti C, Gilardini L, Pontiggia B, Morabito F, Mazzilli G, Viberti G.
    Nutr Metab Cardiovasc Dis; 2006 May; 16(4):256-62. PubMed ID: 16679217
    [Abstract] [Full Text] [Related]

  • 22. Summary and perspectives on impaired glucose tolerance.
    Genuth S.
    Diabet Med; 1996 May; 13(3 Suppl 2):S29-31. PubMed ID: 8689860
    [Abstract] [Full Text] [Related]

  • 23. Type II Diabetes Mellitus and impaired glucose tolerance in Yemen: prevalence, associated metabolic changes and risk factors.
    Al-Habori M, Al-Mamari M, Al-Meeri A.
    Diabetes Res Clin Pract; 2004 Sep; 65(3):275-81. PubMed ID: 15331208
    [Abstract] [Full Text] [Related]

  • 24. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population.
    Bergmann A, Li J, Wang L, Schulze J, Bornstein SR, Schwarz PE.
    Horm Metab Res; 2007 Sep; 39(9):677-82. PubMed ID: 17846976
    [Abstract] [Full Text] [Related]

  • 25. Type 2 diabetes mellitus and other cardiovascular risk factors are no more common during menopause: longitudinal study.
    Soriguer F, Morcillo S, Hernando V, Valdés S, Ruiz de Adana MS, Olveira G, Fuentes EG, González I, Tapia MJ, Esteva I, Rojo-Martínez G.
    Menopause; 2009 Sep; 16(4):817-21. PubMed ID: 19387417
    [Abstract] [Full Text] [Related]

  • 26. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus.
    da Silva RC, Miranda WL, Chacra AR, Dib SA.
    J Diabetes Complications; 2007 Sep; 21(2):84-92. PubMed ID: 17331856
    [Abstract] [Full Text] [Related]

  • 27. Cardiometabolic profile of people screened for high risk of type 2 diabetes in a national diabetes prevention programme (FIN-D2D).
    Saaristo T, Moilanen L, Jokelainen J, Korpi-Hyövälti E, Vanhala M, Saltevo J, Niskanen L, Peltonen M, Oksa H, Cederberg H, Tuomilehto J, Uusitupa M, Keinänen-Kiukaanniemi S.
    Prim Care Diabetes; 2010 Dec; 4(4):231-9. PubMed ID: 21134669
    [Abstract] [Full Text] [Related]

  • 28. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group.
    Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
    [Abstract] [Full Text] [Related]

  • 29. Impaired glucose tolerance, impaired fasting glycaemia and cardiovascular risk.
    Sanusi H.
    Acta Med Indones; 2004 Jun; 36(1):36-41. PubMed ID: 15673935
    [Abstract] [Full Text] [Related]

  • 30. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study.
    Janssen PG, Gorter KJ, Stolk RP, Rutten GE.
    Prim Care Diabetes; 2007 Jun; 1(2):69-74. PubMed ID: 18632022
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group.
    JAMA; 2003 Jul 23; 290(4):486-94. PubMed ID: 12876091
    [Abstract] [Full Text] [Related]

  • 35. Family history of diabetes and effectiveness of lifestyle counselling on the cardio-metabolic risk profile in individuals at high risk of Type 2 diabetes: 1-year follow-up of the FIN-D2D project.
    Rautio N, Jokelainen J, Oksa H, Saaristo T, Peltonen M, Puolijoki H, Tuomilehto J, Vanhala M, Moilanen L, Uusitupa M, Keinänen-Kiukaanniemi S.
    Diabet Med; 2012 Feb 23; 29(2):207-11. PubMed ID: 21781153
    [Abstract] [Full Text] [Related]

  • 36. [Epidemiology on impaired glucose tolerance].
    Tominaga M.
    Nihon Rinsho; 1996 Oct 23; 54(10):2643-8. PubMed ID: 8914422
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
    Chiasson JL.
    Endocr Pract; 2006 Oct 23; 12 Suppl 1():25-30. PubMed ID: 16627376
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.